TradingFloor AI · Stock Terminal

AMRX - Ticker AI Digest

Amneal Pharmaceuticals, Inc. Class A Common Stock 📰 3
17.54000000 | Today -2.61% ●
Desk Snapshot GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
Amneal Pharmaceuticals, Inc. Class A Common Stock in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, Today’s AI, and the deeper desks.
AMRX Data 2026-08-31 Preview Mode
Core Deck
Deep Dive Modules
Home

Digested News

Today's Catalysts (AMRX) 3
AMRX 20:50
Amneal Pharmaceuticals, Inc. Class A Common Stock
Eli Lilly, Regeneron named to FDA pilot program to boost US drug manufacturing
AMRX 08:05
Amneal Pharmaceuticals, Inc. Class A Common Stock
1 Mooning Stock Worth Your Attention and 2 We Question
AMRX 06:00
Amneal Pharmaceuticals, Inc. Class A Common Stock
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Admission 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 2
AMRX 11:48
Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals' Romidepsin Injection Solution Wins FDA Approval
AMRX 11:00
Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
BlockListing 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Circular 0
No items for this category on selected date.
ClinicalTrial 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 1
AMRX 15:16
Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal and Pfizer GLP-1 Deal: New Growth Lever?
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
DirectorateChange 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Dividend 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 2
AMRX 20:50
Amneal Pharmaceuticals, Inc. Class A Common Stock
Eli Lilly, Regeneron named to FDA pilot program to boost US drug manufacturing
AMRX 14:30
Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Stock Up on FDA Nod for Romidepsin Injection Solution
Form83 0
No items for this category on selected date.
GeneralMeeting 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
IssueOfEquity 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 2
AMRX 04:07
Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals (AMRX) Is Up 17.8% After CREXONT Phase 4 Gains And New Oncology Launch
AMRX 13:09
Amneal Pharmaceuticals, Inc. Class A Common Stock
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
Litigation 0
No items for this category on selected date.
MonthlyFactsheet 0
No items for this category on selected date.
NAV 0
No items for this category on selected date.
NameChange 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
OwnShares 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
ProfitWarning 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Prospectus 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
AMRX 11:00
Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
SchemeOfArrangement 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
TVR 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
US News 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 1
AMRX 20:56
Amneal Pharmaceuticals, Inc. Class A Common Stock
FDA Seeks Updated Labeling for Testosterone Therapies
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 1
AMRX 08:05
Amneal Pharmaceuticals, Inc. Class A Common Stock
1 Mooning Stock Worth Your Attention and 2 We Question
All Market News (Last 30 Days) 23
AMRX 20:50
Amneal Pharmaceuticals, Inc. Class A Common Stock
Eli Lilly, Regeneron named to FDA pilot program to boost US drug manufacturing
AMRX 08:05
Amneal Pharmaceuticals, Inc. Class A Common Stock
1 Mooning Stock Worth Your Attention and 2 We Question
AMRX 06:00
Amneal Pharmaceuticals, Inc. Class A Common Stock
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
AMRX 11:06
Amneal Pharmaceuticals, Inc. Class A Common Stock
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
AMRX 20:56
Amneal Pharmaceuticals, Inc. Class A Common Stock
FDA Seeks Updated Labeling for Testosterone Therapies
AMRX 10:16
Amneal Pharmaceuticals, Inc. Class A Common Stock
1 Small-Cap Stock for Long-Term Investors and 2 We Find Risky
AMRX 04:07
Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals (AMRX) Is Up 17.8% After CREXONT Phase 4 Gains And New Oncology Launch
AMRX 12:40
Amneal Pharmaceuticals, Inc. Class A Common Stock
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?
AMRX 13:09
Amneal Pharmaceuticals, Inc. Class A Common Stock
3 Russell 2000 Stocks with Open Questions
AMRX 13:09
Amneal Pharmaceuticals, Inc. Class A Common Stock
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
AMRX 18:05
Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase
AMRX 15:16
Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal and Pfizer GLP-1 Deal: New Growth Lever?
AMRX 14:56
Amneal Pharmaceuticals, Inc. Class A Common Stock
Is Amneal a Buy Before Rytary Generic Erosion?
AMRX 14:53
Amneal Pharmaceuticals, Inc. Class A Common Stock
What's Driving Amneal's 2026 Growth Outlook?
AMRX 04:05
Amneal Pharmaceuticals, Inc. Class A Common Stock
How The Amneal Pharmaceuticals (AMRX) Story Is Shifting With Biosimilars And 2026 Expectations
AMRX 14:30
Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Stock Up on FDA Nod for Romidepsin Injection Solution
AMRX 11:00
Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
AMRX 02:33
Amneal Pharmaceuticals, Inc. Class A Common Stock
Why Amneal (AMRX) Stock Is Trading Up Today
AMRX 16:25
Amneal Pharmaceuticals, Inc. Class A Common Stock
3 Profitable Stocks with Open Questions
AMRX 11:48
Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals' Romidepsin Injection Solution Wins FDA Approval
AMRX 11:00
Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
AMRX 12:40
Amneal Pharmaceuticals, Inc. Class A Common Stock
Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now?
AMRX 11:00
Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026

Today's AI

AMRX · Agentic Market Intelligence

AMRX intelligence is listening.

The engine is monitoring news, price structure, forecasts and financial changes. New scored evidence will appear here against this stock automatically.

Live catalyst scoringAI price pathsRisk-aware triggersFinancial blend
AI bias0.0
Bullish0
Bearish0
Today's AI Starts With News

3 live catalysts is opening Today’s AI for AMRX.

Start with the live headline tape first. Today’s AI findings sit next, and the AI Blend stack drops lower once the news context is framed. Financial Forecastist now feeds the blend too.
Live Tape Data 2026-08-31 Blend Lower Down
Read the alert tape first, then open Today’s AI findings. Use AI Expand on any card to open the AI explanation, results tables and financial forecast rows instantly.
3 Today
Front Of Desk
Amneal Pharmaceuticals, Inc. Class A Common Stock has fresh news flow live now, so Today’s AI is leading with the tape before the blended signal stack below.
20:50 Today's Catalyst Eli Lilly, Regeneron named to FDA pilot program to boost US drug manufacturing 08:05 Today's Catalyst 1 Mooning Stock Worth Your Attention and 2 We Question 06:00 Today's Catalyst Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
Single-Ticker Today's AI
AMRX signal theatre built from scored market catalysts, automated AI forecasts, financial forecasting and live trigger logic.

This is the ticker-specific Today’s AI desk for Amneal Pharmaceuticals, Inc. Class A Common Stock. It compresses the live catalyst tape, bullish and bearish scoring, AI price forecasts, financial forecasting and trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI + Financial Blend Buy / Sell Trigger Engine Today's AI Findings
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full AMRX Today’s AI cockpit.

Subscription turns this tab into a live signal desk with today’s news findings at the top, AI plus financial blend comparisons at the bottom, buy and sell trigger logic, and the full findings ledger behind every scored row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific Today’s AI stack, sentiment gauges, AI blend stage, and the full findings ledger for AMRX on 2026-08-31.

Fundamentals Matrix

About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

🌐 Visit Official Website ↗

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
5.5B
Enterprise Value
8.0B
Public Float
55.9
Broker Target
17.25
Shares Out
319.3M
Long Interest
100
Short Interest
0
Exchange
NASDAQ
Currency Code
USD
ISIN
US03168L1052
Ex-Dividend
-
Yield
0.00%
Dividend Rate
-
EPS
0.37
Market
NASDAQ
Standard Lists
Not currently ranked
Sector
Pharmaceuticals and BiotechnologyUS fundamentals
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

3 live alerts now opens the financials desk for AMRX.

Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts Data 2026-08-31 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
3 Alerts
Front Of Desk
Amneal Pharmaceuticals, Inc. Class A Common Stock has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
20:50 Today's Alert Eli Lilly, Regeneron named to FDA pilot program to boost US drug manufacturing 08:05 Today's Alert 1 Mooning Stock Worth Your Attention and 2 We Question 06:00 Today's Alert Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
-
Earnings Date
-
Net Debt
2.4B
Cash
310.9M
EPS
0.37
Net Income
72.1M
Revenue
3.0B
Enterprise Value
8.0B
Trailing PE
46.3514
Forward PE
6.2972
Price Sales TTM
1.798
Price Book MRQ
105.446
EV Revenue
2.619
EV EBITDA
12.7424
Financial Forecastist

Improving financial engine

Revenue is accelerating +3.9% against the prior comparable period. Net margin is expanding by 6.9 pts. Net debt is coming down +0.9%.

Revenue +3.9% Net Income +412.5% FCF +290.2% Current Ratio 2.47x Forward Rev 812.4M
Improving
Quarter Revenue
722.5M
+3.9%
vs prior comparable quarter
Net Margin
+8.6%
+6.9 pts
profitability pulse
Free Cash Flow
-42.6M
+290.2%
cash conversion
Net Debt / EBITDA
14.1x
-0.9%
lower is cleaner
Revenue Engine

Latest quarter printed 722.5M with the top line pushing higher against the last comparable period.

Profit Stack

Net income landed at 62.5M and the margin profile is broadening. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 197.7M while net debt is 2.5B. The leverage stack is cleaning up.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q3 2025
Consensus
773.8M
Revenue Path
0.14
EPS / Earnings
Growth cue -0.1%
Q1 2026
Consensus
716.8M
Revenue Path
0.17
EPS / Earnings
Growth cue -0.2%
Q2 2026
Consensus
765.2M
Revenue Path
0.23
EPS / Earnings
Growth cue -0.1%
Q3 2026
Consensus
812.4M
Revenue Path
0.25
EPS / Earnings
Growth cue +0.5%
FY 2026
Consensus
3.1B
Revenue Path
0.99
EPS / Earnings
Growth cue +0.2%
FY 2027
Consensus
3.3B
Revenue Path
1.12
EPS / Earnings
Growth cue +0.1%

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q1 2026 722.5M 62.5M -42.6M 2.5B
Q4 2025 814.3M 35.1M 87.1M 2.4B
Q3 2025 784.5M 2.4M 103.4M 2.5B
Q2 2025 724.5M 22.4M 57.3M 2.5B
Q1 2025 695.4M 12.2M -10.9M 2.5B
Q4 2024 730.5M -31.1M 95.0M 2.5B

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2025 3.0B 72.1M 603.9M 269.9M
FY 2024 2.8B -116.9M 439.8M 220.1M
FY 2023 2.4B -84.0M 500.8M 276.4M
FY 2022 2.2B -130.0M 440.2M -25.5M
FY 2021 2.1B 10.6M 401.1M 194.1M

Structure DNA

Market Structure DNA

Balanced Structure profile with trend runway open

Price is 93.0% through the 52-week range, +21.9% vs 50DMA and +34.9% vs 200DMA. 100.0% of the register is locked by institutions and insiders, leaving 0.0% free float. Capital rhythm reads no cadence with forward yield near 0.0% and payout around 0.0%.

Trend runway open Institutional gravity Moderate income rhythm As Of 2026-07-06
Balanced Structure
Structure Score
75.7 / 100
Balanced Structure
Trend Stack
+21.9% / +34.9%
vs 50DMA / 200DMA
52W Position
93.0%
auction position inside the yearly range
Ownership Lock
100.0%
52.1% institutions | 49.0% insiders
Pressure Pocket
3.8% short float
Short ratio 4.3x | monthly +5.1%
Capital Rhythm
No cadence
Yield 0.0% | payout 0.0%
Trend Runway

Implied spot is 17.15 with the stock +21.9% vs 50DMA and +34.9% vs 200DMA. The tape is sitting 93.0% through the 52-week range, which frames the regime as trend runway open.

Ownership Register

Institutions hold about 52.1% and insiders about 49.0%, locking roughly 100.0% of the register and leaving 0.0% in free float. That reads as institutional gravity.

Pressure Pocket

Short pressure is running near 3.8% of float with short ratio 4.3x and monthly change +5.1%. That gives us a read on whether the tape is clean, crowded, or coiled.

Capital Rhythm

Dividend cadence reads no cadence with - event(s) in the last full year, a five-year average of -, and stability score 0.0/100. Forward yield sits near 0.0% while payout is around 0.0%.

Structure Score

One-glance gauge for the current market-structure regime.

Pillar Radar

Trend, ownership, pressure, and capital rhythm mapped on one wheel.

Position And Float Balance

Shows whether the stock is extended, tightly held, or carrying capital-return support.

Dividend Cadence Tape

Historical dividend-event counts help reveal how dependable the income rhythm has been.

Dividend Cadence Ledger

No cadence
Year Dividend Count Context
Dividend history has not been normalized yet.

Structure Facts

Live Snapshot
Implied Spot
17.15
derived from market cap / shares
52W High
17.86
upper auction edge
52W Low
7.67
lower auction edge
Beta
1.26
volatility character
Shares Out
319.3M
fully diluted count
Shares Float
178.4M
tradable register
Shares Short
7.9M
borrowed stock
Short Ratio
4.3x
days-to-cover style read
Ex-Dividend
-
next ex-date not supplied
Dividend Pay
-
payment date not supplied
Last Split
-
split date not supplied

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
55.6047
Institutions As Of
2026-05-31
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
0
Sale TR1
0
Broker Coverage Rows
0
Institution Holders Tracked
40
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data · AMRX · Last 30 Days

Short D · 12/26 EMA spread with 9 signal

Red histogram bars show short loading accelerating. Green bars show short covering accelerating. The two lines expose the crossover before the raw holder table does.

Short D waiting

Building AMRX short-momentum read

Short D compares the ticker’s disclosed short-position momentum with its own signal line.

Short D—
Signal—
Momentum—

Declared Short Holders

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

The alert tape opens the door for AMRX, and AI Charts sits just below.

Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape Data 2026-08-31 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
3 Today
Catalyst Pulse
Amneal Pharmaceuticals, Inc. Class A Common Stock has fresh news flow live now, so the tape is framing the chart workspace below.
20:50 Today's Catalyst Eli Lilly, Regeneron named to FDA pilot program to boost US drug manufacturing 08:05 Today's Catalyst 1 Mooning Stock Worth Your Attention and 2 We Question 06:00 Today's Catalyst Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
AI Charts Studio
AMRX Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-08-31 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
Desk Snapshot Member Login
AI AutoDetection Automatic bull / bear chart read
Detected market structure
Analysing selected range
Why this call
Waiting for sufficient price history.
Invalidation
—
Updates with the timeframe.
Bull caseCalculating upside confirmation.
Bear caseCalculating downside confirmation.
Indicators0
Technicals0
RSI Gauge
Price Change
AI Forecast